PORTFOLIO OVERVIEW
30+ years of biotech investing. Listed in Switzerland and Germany.
Portfolio breakdown
POSITIONS
Ionis Pharmaceuticals
14.60%
Argenx SE
14.10%
Revolution Medicines
9.30%
Neurocrine Biosciences
8.80%
Alnylam Pharmaceuticals
7.10%
Vertex Pharmaceuticals
6.40%
Agios Pharmaceuticals
5.30%
Incyte
4.40%
Scholar Rock
4.30%
Akero Therapeutics
4.00%
Immunocore
3.60%
Avidity Biosciences
3.40%
Celldex Therapeutics
3.30%
Beam Therapeutics
2.50%
Rivus Pharmaceuticals
1.90%
Edgewise Therapeutics
1.60%
Relay Therapeutics
1.60%
Biohaven
1.50%
Wave Life Sciences
1.10%
Annexon
0.60%
Macrogenics
0.60%
Financial Health
Profitable
Financed to break even / product at market
Pipeline companies / additional financing required (> 2 years)
Pipeline companies / acute financing required (<2 years)
Disease area
Orphan Diseases
Inflammation & Immunology
Oncology
Neurological Diseses
Cardiovascular Diseases
market capitalization (in usd)
> 30 bn
Private
5 - 30 bn
500 mn - 1 bn
1 - 5 bn
< 500 mn
Technology
Small Molecule
Antibody
RNA
Gene- and cell therapy
Facts & key figures
Investment Focus
Innovative biotechnology companies developing differentiated therapies
Primarily invested in listed biotechnology companies, with selective private investments
20–35 target participations
5–8 core positions with meaningful portfolio weights
suitability & risk profile
Designed for long-term investors (5+ years) willing to accept equity risk typical of the biotech sector.
Lower Risk
Higher Risk
Risk metrics (3Y)
1.2
Beta (3Y)
26.7%
Volatility (3Y)
13.5%
Tracking Error
0.35
Sharpe Ratio
NBI (Nasday Biotechnology Index) is used as the benchmark and the reference currency is CHF.
general information
Investment manager
Bellevue Asset Management AG
Custodian bank
Bank Julius Bär AG
Launch date
09.11.1993
Fiscal year end
December 31
Management fee
1.10% p.a.
Legal form
Incorporate company
SFDR category
Article 8
Benefits & risks
Access to global biotech growth
Diversified portfolio of profitable and pipeline companies
Experienced investment management
Dividend policy (~5%)
Equity volatility
Biotech sector swings
Currency risks
Discount/premium to NAV
Up to 15% leverage possible